Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 1999

View Archived Issues

Patent protection received for newest addition to Molecular Biosystems' pipeline

Neurocrine discontinues development of DHEA; to advance other programs

Epicoat technology granted U.S. patent protection

Celgene and NCI collaborate on thalidomide study in glioblastoma

FDA ruling upholds orphan drug exclusivity for Avonex

Two Boehringer Ingelheim drugs to be copromoted by Abbott in U.S.

Wyeth-Ayerst and Neurocrine to develop drugs targeting neurotransmitter transporters

Wyeth-Ayerst to market Abelcet in the U.K.

Ontogeny establishes research collaborations for skin cancer therapy

Medtronic and Cognetix to develop new treatment for epilepsy

Rhone-Poulenc Rorer describes new hypoglycemic series

Antiulcer PGE analogues developed at Taisho

Taisho scientists isolate and and characterize new antifungal agent

New Astra compounds for the therapy of 5-HT-mediated disorders

Prokinetic and analgesic benzamides developed at French laboratory

MGI-114 in combination with CPT-11 enters clinical evaluation

Randomized comparison of aspirin, aspirin + warfarin and aspirin + ticlopidine following stenting

MMP inhibitor-chemotherapeutic drug combination suppresses tumor dissemination in mice

Gene therapy with human HGF proves simple, safe and effective in rats with cirrhosis

Toagosei researchers identify potent antitumor MAb

Lilly delays phase III clinical trials of migraine compound

FDA advisory committee declines to recommend approval of Locilex

Licensing opportunity from BTG: fatty acid-peptide conjugates for use in vaccines

Single-isomer version of epilepsy Rx developed at ABS

Available for licensing from BTG: immune function modulator with applications in dermatology

GenoPlex licenses rights to AD discoveries from MGH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.